Skip to main content
OliX Pharmaceuticals, Inc. logo

OliX Pharmaceuticals, Inc. — Investor Relations & Filings

Ticker · 226950 ISIN · KR7226950004 KO Manufacturing
Open in API
Filings indexed 365 across all filing types
Latest filing 2025-03-07 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 226950

About OliX Pharmaceuticals, Inc.

https://olixpharma.com

OliX Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company specializing in the development of therapeutics based on RNA interference (RNAi) technology. The company leverages its proprietary asymmetric siRNA (asiRNA) platform to create treatments that selectively silence disease-causing genes. Its research and development efforts are focused on building a robust pipeline of drug candidates targeting a variety of illnesses with high unmet medical needs. The pipeline has a particular emphasis on ophthalmic and dermal disorders, with key programs addressing conditions such as hypertrophic scars, age-related macular degeneration (AMD), and other fibrotic and ocular diseases.

Recent filings

Filing Released Lang Actions
전환청구권행사
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the exercise of conversion rights (전환청구권행사) for convertible bonds. It details the number of shares issued, the conversion price, and the remaining balance of the convertible bonds. This type of filing relates to changes in capital structure and share issuance resulting from debt conversion, which falls under the 'Share Issue/Capital Change' category.
2025-03-07 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean regulatory authorities (Financial Supervisory Service/KRX). This type of filing is specifically used to report insider transactions or changes in share ownership by company directors and executives. According to the provided definitions, this corresponds to 'Director's Dealing' (DIRS).
2025-02-28 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean financial authorities (Financial Supervisory Service/KRX). This type of filing is specifically used to report insider transactions, such as the exercise of stock options by a director or executive, which falls under the category of 'Director's Dealing'.
2025-02-28 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a '주식등의 대량보유상황보고서' (Report on Large Shareholding), which is a standard regulatory filing in South Korea under the Capital Markets Act. It details changes in share ownership by major shareholders and special related parties, including stock sales and stock option exercises. This falls under the 'Major Shareholding Notification' category.
2025-02-28 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report) to a previously filed stock option grant. It details changes to the number of recipients and the number of shares granted. In the context of Korean corporate filings (DART system), this type of disclosure regarding stock option grants and their subsequent amendments falls under general regulatory filings as it does not fit into specific categories like director dealings or proxy statements.
2025-02-28 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and is specifically an amendment ('정정신고') to a previous filing. It details changes to stock option grants, including the number of shares and the list of recipients. In the context of corporate filings, reports regarding stock options, equity compensation, or capital changes that do not fit into specific categories like 'Director's Dealing' (which is for personal trades) are classified as Regulatory Filings (RNS) when they represent official corporate disclosures to financial authorities.
2025-02-28 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.